Evotec (NASDAQ:EVO) Sees Unusually-High Trading Volume – What’s Next?

Shares of Evotec SE (NASDAQ:EVO) saw an uptick in trading volume on Tuesday . 118,691 shares traded hands during trading, a decline of 12% from the previous session’s volume of 134,233 shares.The stock last traded at $4.04 and had previously closed at $4.13.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on EVO. Deutsche Bank Aktiengesellschaft raised Evotec from a “sell” rating to a “hold” rating in a research note on Thursday, April 24th. Royal Bank of Canada reaffirmed an “outperform” rating on shares of Evotec in a research note on Thursday, May 15th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.93.

Evotec Price Performance

The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. The firm has a 50 day moving average price of $3.99 and a 200-day moving average price of $4.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of EVO. BNP Paribas Financial Markets purchased a new position in shares of Evotec during the 4th quarter worth about $27,000. CSS LLC IL bought a new stake in Evotec in the fourth quarter worth about $50,000. Bank of America Corp DE boosted its position in shares of Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after buying an additional 9,289 shares during the period. Lighthouse Investment Partners LLC purchased a new stake in shares of Evotec in the fourth quarter worth approximately $166,000. Finally, ABC Arbitrage SA bought a new stake in shares of Evotec during the 1st quarter worth approximately $260,000. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.